JPRN-UMIN000012074Not yet recruitingPhase 1
Phase I/II trial of S-1+Nedaplatin+Cetuximab for recurrent/metastatic head and neck squamous cell carcinoma - Phase I/II trial of S-1+Nedaplatin+Cetuximab for recurrent/metastatic head and neck cancer
Kyorin University School of Medicine, Department of Otolaryngology0 sites30 target enrollmentStarted: November 18, 2013Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Past history of allergy against S-1, Nedaplati or cetuximab 2) pregnancy or the man who wants partner's pregnancy 3) active double cancer 4) active infection disesase 5) Current administration of Flucytosine, fenitoin or warfarin 6) Positivity for hepatitis B or Hepatitis C antigen 7) severe skin disesase 8) interstitial pneumonia 9) severe diarrhea 10) severe renal disease 11) Other significant disease that in the investigator's opinion would exclude the subject from the trial
Investigators
Similar Trials
Recruiting
Phase 2
Phase II trial of Nedaplatin/S-1/Cetuximab combination therapy for Recurrence or Metastatic Squamous cell carcinoma of the Head and NeckRecurrence or Metastatic Squamous cell carcinoma of the Head and NeckJPRN-UMIN000011497Kinki University Faculty of Medicine, Department of Medical Oncology40
Completed
Phase 2
Phase II trial of S-1 plus Cetuximab combination chemotherapy for advanced recurrent/metastatic carcinoma of the oral cavityAdvanced recurrent/metastatic carcinoma of the oral cavityJPRN-UMIN000024371Osaka University20
Completed
Phase 2
Phase II trial of S-1+oxaliplatin+Cetuximab as first-line treatment in patients with kras-wild type unresectable advanced colorectal cancer - KODK 9colorectal cancerJPRN-UMIN000008963Department of Surgery Keio University School of Medicine35
Completed
Phase 2
Phase II trial of S-1 plus Cetuximab combination therapy in patients inappropriate for platinum-based therapy with recurrent/metastatic squamous cell carcinoma of the head and neckJPRN-UMIN000015123Hokkaido University21
Recruiting
Not Applicable
Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancercolorectal cancerJPRN-UMIN000003703Toho University school of Medicine10